EGFR and non-small cell lung carcinoma: The discovery of EGFR tyrosine kinase inhibitor (EGFR-TKI) effectively prolonged the remission and survival of patients with EGFR sensitive mutations in advanced NSCLC, mainly exon 19 deletions or the L858R point mutation in exon 21.